Bladder Cancer Weekly

March 30, 2026

Videos

Peer-to-Peer Clinical Conversations

Individual Patient Data Analysis Explores Benefit of Adding Immunotherapy to BCG in Bladder Cancer - Ashish Kamat

Ashish M. Kamat

Ashish Kamat discusses a commentary analyzing BCG plus checkpoint inhibitor trials in non-muscle invasive bladder cancer.

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Sarah Psutka

Sarah Psutka discusses cretostimogene grenadenorepvec expanded access program with Ashish Kamat.

Beyond the Abstracts

A Multi-Modal Approach for Decision Making in Bladder Cancer - Beyond the Abstract

Oncologic Outcomes of Neoadjuvant Chemotherapy and Lymph Node Dissection with Partial Cystectomy for Muscle-Invasive Bladder Cancer - Beyond the Abstract

Conference Coverage

SES AUA 2026: Implementation of Patient Reported Outcomes as a NMIBC Clinical Trial Endpoint

EAU 2026: Reduced Versus Full Dose BCG Maintenance in NMIBC Patients Treated with Full Dose Induction: A Matched Analysis

EAU 2026: Impact of BCG Failure Pattern on Oncologic Outcomes of Intravesical Gemcitabine and Docetaxel in High-Risk NMIBC: A Multicenter European Study

ASCO GU 2026: Trastuzumab Deruxtecan in Pretreated Patients with HER2-Expressing Bladder Cancer: Final Results from the Bladder Cancer Cohort in Part 1 of DESTINY-PanTumor02

ASCO GU 2026: SWOG-2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with MIBC (BRIGHT)

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.

Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.

FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model.

Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).

Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.

De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration.

Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guérin induction.

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.

Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy.

Refining BCG-failure classifications in non-muscle-invasive bladder cancer.

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract

Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?

Exploring the Influence of the Bladder Microbiome on BCG Immunotherapy Outcomes for High-Risk Non Muscle Invasive Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC